Key result
Pharmacological challenge with isoproterenol and caffeine in RyR2(S/S) mice reduced conduction velocity and maximum action potential upstroke rates, revealing a strongly arrhythmic phenotype.
Why the study?
Does pharmacological challenge with isoproterenol and caffeine alter conduction velocity and induce arrhythmias in murine RyR2-P2328S hearts compared to wild-type?
Does pharmacological challenge with isoproterenol and caffeine alter conduction velocity and induce arrhythmias in murine RyR2-P2328S hearts compared to wild-type?
Altered ventricular myocardial conduction velocity following adrenergic challenge may provide an arrhythmogenic substrate in genetic RyR2 alterations associated with CPVT.
Does not support practice change in CPVT; leaves open conduction slowing as RyR2 arrhythmia substrate.
INTRODUCTION: The familial condition catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by episodic bidirectional ventricular tachycardia (BVT), polymorphic ventricular tachycardia (PVT), and ventricular fibrillation following adrenergic challenge. It is associated with mutations involving the cardiac ryanodine receptor (RyR2). METHODS AND RESULTS: We explored for a slowing of myocardial conduction that could potentially result in a substrate for the spontaneous arrhythmogenesis that was observed following introduction of isoproterenol and caffeine in intrinsically beating murine RyR2-P2328S hearts. Such pharmacological challenge increased the number of arrhythmic episodes in electrocardiographic recordings from intact anesthetized mice, with the greatest effects in the homozygote RyR2(S/S). Arrhythmias took the form of bigeminy, BVT, monomorphic ventricular tachycardia, and PVT, as found in human CPVT. Ventricular epicardial conduction velocities (CVs) measured using multielectrode array recordings and maximum action potential upstroke rates, (dV/dt)(max), measured using intracellular microelectrodes were indistinguishable in untreated wild-type (WT) and RyR2(S/S). Pharmacological challenge of RyR2(S/S), but not WT hearts, then reduced CV and (dV/dt)(max) and also revealed a strongly arrhythmic phenotype. There was no evidence of gross structural or fibrotic changes in either RyR2(+/S) or RyR2(S/S) hearts on light microscopy. CONCLUSIONS: We associate altered ventricular myocardial CV potentially resulting in arrhythmogenic substrate with arrhythmic properties associated with genetic RyR2 alterations for the first time.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2012) studied Catecholaminergic polymorphic ventricular tachycardia (CPVT). Isoproterenol and caffeine vs. Wild-type (WT) hearts was evaluated on Ventricular epicardial conduction velocities (CVs) and maximum action potential upstroke rates. Pharmacological challenge with isoproterenol and caffeine in RyR2(S/S) mice reduced conduction velocity and maximum action potential upstroke rates, revealing a strongly arrhythmic phenotype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: